181 related articles for article (PubMed ID: 35280727)
1. Adjuvant Therapy With PD1/PDL1 Inhibitors for Human Cancers: A Systematic Review and Meta-Analysis.
Jin Y; Wei J; Weng Y; Feng J; Xu Z; Wang P; Cui X; Chen X; Wang J; Peng M
Front Oncol; 2022; 12():732814. PubMed ID: 35280727
[TBL] [Abstract][Full Text] [Related]
2. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W
J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and anti-angiogenic therapy for solid tumors: A systematic review and meta-analysis.
Xian F; Wu J; Zhong L; Xu G
Medicine (Baltimore); 2023 Mar; 102(10):e33204. PubMed ID: 36897735
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors in cancer.
Mo DC; Liang ZY; Chen L; Huang JF; Luo PH; Wang HL
Exp Ther Med; 2022 Dec; 24(6):749. PubMed ID: 36561965
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis.
Liu J; Zhong Y; Peng S; Zhou X; Gan X
Onco Targets Ther; 2018; 11():8623-8632. PubMed ID: 30584321
[TBL] [Abstract][Full Text] [Related]
6. The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal Therapy.
Li H; Wang Z; Zhang Y; Sun G; Ding B; Yan L; Liu H; Guan W; Hu Z; Wang S; Cheng F; Xu H; Zhang X; Ye Z
J Cancer; 2019; 10(14):3102-3111. PubMed ID: 31289580
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and antiangiogenic drugs for hepatocellular carcinoma: a systematic review and meta-analysis.
Xian F; Wu J; Yuan YL; Bie J; Xu GH
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(4):1494-1502. PubMed ID: 36876689
[TBL] [Abstract][Full Text] [Related]
8. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis.
Jiang Q; Huang J; Zhang B; Li X; Chen X; Cui B; Li S; Guo G
Front Immunol; 2022; 13():801909. PubMed ID: 35309350
[TBL] [Abstract][Full Text] [Related]
10. Can adjuvant immune checkpoint inhibitors improve the long-term outcomes of hepatocellular carcinoma with high-risk recurrent factors after liver resection? A meta-analysis and systematic review.
Hu L; Kong Y; Qiao Y; Wang A
Front Oncol; 2024; 14():1374262. PubMed ID: 38854716
[TBL] [Abstract][Full Text] [Related]
11. Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.
Su CW; Hou MM; Huang PW; Chou YC; Huang BS; Tseng JH; Hsu CW; Chang TC; Lin SM; Lin CC
Am J Cancer Res; 2022; 12(4):1606-1620. PubMed ID: 35530291
[TBL] [Abstract][Full Text] [Related]
12. The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis.
Chang CH; Shih AC; Chang YH; Chen HY; Chao YT; Hsu YC
Front Oncol; 2021; 11():759497. PubMed ID: 34868974
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy.
Liu J; Chen Z; Li Y; Zhao W; Wu J; Zhang Z
Front Pharmacol; 2021; 12():731798. PubMed ID: 34539412
[TBL] [Abstract][Full Text] [Related]
14. Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study.
Sun Y; Jiang L; Wen T; Guo X; Shao X; Qu H; Chen X; Song Y; Wang F; Qu X; Li Z
Front Pharmacol; 2021; 12():670900. PubMed ID: 34489691
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis.
Addeo A; Banna GL; Metro G; Di Maio M
Front Oncol; 2019; 9():264. PubMed ID: 31058078
[No Abstract] [Full Text] [Related]
16. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
17. PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review).
Tang Q; Zhao S; Zhou N; He J; Zu L; Liu T; Song Z; Chen J; Peng L; Xu S
Int J Oncol; 2023 Apr; 62(4):. PubMed ID: 36866750
[TBL] [Abstract][Full Text] [Related]
18. The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
Deng S; Yang Q; Shu X; Lang J; Lu S
Front Pharmacol; 2019; 10():1063. PubMed ID: 31607917
[No Abstract] [Full Text] [Related]
19. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
[TBL] [Abstract][Full Text] [Related]
20. Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors.
Wu Y; Lin L; Liu X
Dis Markers; 2020; 2020():7291586. PubMed ID: 32587640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
